Actively Recruiting
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Led by Zhejiang Cancer Hospital · Updated on 2025-02-18
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)
CONDITIONS
Official Title
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily joined the study, signed informed consent, and have good compliance
- Aged 18 to 80 years at the time of consent with ECOG Performance Status score of 0-2
- Histopathologically confirmed diffuse large B-cell lymphoma with evaluable lesions
- Did not achieve complete remission or relapsed after second-line therapy
- Female patients of reproductive age agree to use birth control during the study and for six months after, with a negative serum pregnancy test within 7 days prior to enrollment and non-lactating
- Male patients agree to use contraception during the study and for six months after completion
You will not qualify if you...
- Pathological subtypes: primary central nervous system DLBCL or primary mediastinal large B-cell lymphoma
- Severe or uncontrolled comorbid conditions including symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer disease, or severe hemorrhagic disorders
- History of active immune or autoimmune disease, or history of allogeneic organ or hematopoietic stem cell transplantation
- Active infection requiring systemic antimicrobial therapy within 14 days before starting treatment
- Current participation in other clinical studies or initiation of study drugs less than 4 weeks after previous trial treatment
- Presence of concomitant diseases that may seriously endanger safety or interfere with study completion, or deemed unsuitable by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
H
Haifeng Yu, MD
CONTACT
H
Haiyan Yang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here